Lexicon Pharma (LXRX) Pivotal inTandem2 Phase 3 Trial for Sotagliflozin Met Primary Endpoint
Tweet Send to a Friend
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that its pivotal inTandem2 Phase 3 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
